Chinese drug makers landed 33 licensing deals with overseas pharmaceutical firms, with transactions totalling US$36.2 billion ...

U.S. National Economic Council Director Kevin Hassett on Thursday dismissed the possibility of China retaliating to tariffs ...

在全球生物医药行业快速发展的背景下，中国Biotech企业正面临前所未有的机遇与挑战。为帮助企业应对融资难、法律风险、管线设计脱节及市场竞争同质化等核心痛点，ChinaBio®生物医药产业国际合作大会将于2025年4月23-24日在上海隆重举行，并于 ...

Novo Holdings CEO Kasim Kutay says China has "really moved up the value chain" in healthcare. "We've seen many others ...

China continues to boost pharmaceutical innovation through regulatory reforms and as a result, "the pace of new drug ...

BEIJING, March 27 (Xinhua) -- Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster ...

Judging by the present cost of production at the clinical research stage, Cheng, who previously worked as a biological ...

China will remain an attractive market for companies from the United States, as the country's focus on technological ...

Bayer's AI Innovation Platform (AIIP), powered by Google Cloud technology, streamlines the development of AI-driven medical ...

Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster their global competitiveness.

Investing.com -- The latest tariffs imposed by the Trump administration are not a major concern for the China healthcare ...